Drugs / REP 2139-Mg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05683548 | — | chronic hepatitis B virus infection, cirrhosis of liver, esophageal varices, hepatitis D virus infection +1 | Replicor Inc. | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REP 2139-Mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683548 ↗ |
| Known as | REP | “BACKGROUND & AIMS: REP 2139-Mg (REP), a nucleic acid polymer, blocks HBV subviral particle assembly and HDV replication.” PMID 41205755 ↗ Nov 2025 |
| Action | Inhibit | “blocks HBV subviral particle assembly and HDV replication” PMID 41205755 ↗ Nov 2025 |
| Modality | Oligonucleotide (other) | “BACKGROUND & AIMS: REP 2139-Mg (REP), a nucleic acid polymer, blocks HBV subviral particle assembly and HDV replication.” PMID 41205755 ↗ Nov 2025 |
| Route | Subcutaneous | “once weekly regimen of subcutaneously (SC) administered REP 2139-Mg” NCT05683548 ↗ |